Andrew C. Weiss (Idorsia Ltd. (SIX: IDIA))

Weiss, Andrew C. (Idorsia 201706– SVP + Head Investor Relations + Corporate Communications before Actelion)

	Organisation	Idorsia Ltd. (SIX: IDIA)
	Group	Idorsia (Group)
	Former/major organisation	Actelion (Group)
	Group	Johnson & Johnson (JnJ) (Group)
	Product	Tracleer®
	Product 2	Uptravi®

Record changed: 2024-07-04

Picture biomindz TRON LSE Mainz Translation Cancer Immunotherapy 650x200px

More documents for Andrew C. Weiss

[1] Idorsia Ltd.. (7/1/24). "Press Release: Idorsia’s Jeraygo (aprocitentan) Approved in Europe as First and Only ERA for the Treatment of Resistant Hypertension". Allschwil....
[2] Idorsia Ltd.. (3/18/24). "Press Release: Idorsia and Viatris Successfully Close the Transaction for the Global Research and Development Collaboration". Allschwil....
[3] Idorsia Ltd.. (7/21/23). "Press Release: Idorsia Announces a Cost Reduction Initiative to Be Implemented by the End of 2023". Allschwil....
[4] Idorsia Ltd.. (6/20/23). "Press Release: Idorsia Has Secured Bridge Financing in the Amount of CHF 75 Million (Ad hoc announcement pursuant to Art. 53 LR)". Allschwil....
[5] Idorsia Ltd.. (1/9/23). "Press Release: Idorsia Presents at the 41st J.P. Morgan Healthcare Conference – Achievements in 2022 Provide the Foundation for Our Success in 2023". Allschwil....
[6] Idorsia Ltd.. (8/23/19). "Press Release: Clinical Data on Idorsia’s Pipeline Compounds Will Be Presented at the European Society of Cardiology Congress 2019". Allschwil....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]